

Gloria S Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2395278/publications.pdf>

Version: 2024-02-01

96
papers

2,124
citations

201674

27
h-index

254184

43
g-index

97
all docs

97
docs citations

97
times ranked

3584
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2015, 35, S276-S304. | 9.6 | 220 |
| 2 | Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 196, 243.e1-243.e5. | 1.3 | 106 |
| 3 | Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. <i>Seminars in Cancer Biology</i> , 2015, 35, S55-S77. | 9.6 | 95 |
| 4 | IGF2 signaling and regulation in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 371-377. | 7.2 | 92 |
| 5 | Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2999-3010. | 7.0 | 85 |
| 6 | Evaluation of a Streamlined Oncologist-Led <i>BRCA</i> Mutation Testing and Counseling Model for Patients With Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1300-1307. | 1.6 | 76 |
| 7 | Potential of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice. <i>Clinical Cancer Research</i> , 2006, 12, 298-304. | 7.0 | 75 |
| 8 | Total laparoscopic hysterectomy: body mass index and outcomes. <i>Obstetrics and Gynecology</i> , 2003, 102, 1384-1392. | 2.4 | 64 |
| 9 | Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2007, 107, 513-517. | 1.4 | 61 |
| 10 | Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2012, 124, 21-25. | 1.4 | 57 |
| 11 | A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2018, 149, 585-591. | 1.4 | 53 |
| 12 | Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736. | 7.1 | 52 |
| 13 | Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624. | 7.1 | 49 |
| 14 | Integrated mutational landscape analysis of uterine leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, . | 7.1 | 48 |
| 15 | Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2012, 124, 26-30. | 1.4 | 45 |
| 16 | RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma. <i>Clinical Cancer Research</i> , 2016, 22, 4676-4686. | 7.0 | 37 |
| 17 | SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. <i>Gynecologic Oncology</i> , 2017, 146, 179-186. | 1.4 | 37 |
| 18 | Site Specificity of Short-Term and Long-Term Habituation in the Tail-Elicited Siphon Withdrawal Reflex of <i>Aplysia</i> . <i>Journal of Neuroscience</i> , 1996, 16, 4923-4932. | 3.6 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. <i>Cancer Causes and Control</i> , 2016, 27, 737-748. | 1.8 | 34 |
| 20 | Abstract 5020: Potential lifestyle intervention in inner city women with endometrial cancer: A pilot study. , 2011, , . | | 34 |
| 21 | Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer. <i>PLoS ONE</i> , 2014, 9, e100165. | 2.5 | 33 |
| 22 | Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020, 11, 560-570. | 1.8 | 32 |
| 23 | Co-expression of GPR30 and ER β and their association with disease progression in uterine carcinosarcoma. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 242.e1-242.e5. | 1.3 | 31 |
| 24 | Downregulation of Filamin A Interacting Protein 1-Like is Associated with Promoter Methylation and Induces an Invasive Phenotype in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2011, 9, 1126-1138. | 3.4 | 31 |
| 25 | PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. <i>Cancer Causes and Control</i> , 2015, 26, 1729-1736. | 1.8 | 31 |
| 26 | Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. <i>Scientific Reports</i> , 2020, 10, 973. | 3.3 | 31 |
| 27 | Total laparoscopic hysterectomy versus total abdominal hysterectomy: cohort review of patients with uterine neoplasia. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2005, 9, 277-86. | 1.1 | 30 |
| 28 | Extragenital adenosarcoma: A case report, review of the literature, and management discussion. <i>Gynecologic Oncology</i> , 2009, 115, 472-475. | 1.4 | 28 |
| 29 | PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. <i>Gynecologic Oncology</i> , 2019, 155, 144-150. | 1.4 | 28 |
| 30 | A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. <i>Cancer</i> , 2022, 128, 1206-1218. | 4.1 | 28 |
| 31 | <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1003-1011. | 4.1 | 25 |
| 32 | Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 529-534. | 2.5 | 23 |
| 33 | Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer. <i>Cancer</i> , 2007, 109, 48-53. | 4.1 | 21 |
| 34 | Clinical utility of chromogranin a and octreotide in large cell neuro endocrine carcinoma of the uterine corpus. <i>Rare Tumors</i> , 2011, 3, 129-131. | 0.6 | 20 |
| 35 | Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2449-2456. | 2.5 | 20 |
| 36 | Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Oncology</i> , 2020, 14, 645-656. | 4.6 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. <i>Gynecologic Oncology</i> , 2009, 113, 327-330. | 1.4 | 19 |
| 38 | The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics. <i>Cancer Causes and Control</i> , 2015, 26, 821-830. | 1.8 | 19 |
| 39 | Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 457.e1-457.e5. | 1.3 | 18 |
| 40 | Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. <i>Gynecologic Oncology</i> , 2017, 147, 145-152. | 1.4 | 18 |
| 41 | Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4845-4853. | 7.0 | 18 |
| 42 | In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 430-438. | 1.4 | 18 |
| 43 | Selective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index. <i>Gynecologic Oncology</i> , 2004, 93, 137-143. | 1.4 | 17 |
| 44 | Population-Based Screening for Endometrial Cancer: Human vs. Machine Intelligence. <i>Frontiers in Artificial Intelligence</i> , 2020, 3, 539879. | 3.4 | 17 |
| 45 | Liposomal Doxorubicin for Treatment of Metastatic Chemorefractory Vulvar Adenocarcinoma. <i>Gynecologic Oncology</i> , 2002, 87, 313-318. | 1.4 | 16 |
| 46 | Total Laparoscopic Hysterectomy. <i>Obstetrics and Gynecology</i> , 2003, 102, 1384-1392. | 2.4 | 15 |
| 47 | Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. <i>Gynecologic Oncology</i> , 2021, 163, 93-99. | 1.4 | 14 |
| 48 | Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age. <i>Gynecologic Oncology</i> , 2004, 95, 196-203. | 1.4 | 13 |
| 49 | PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. <i>Gynecologic Oncology</i> , 2019, 153, 158-164. | 1.4 | 13 |
| 50 | Transforming Growth Factor β 21 and Extracellular Matrix Protease Expression in the Uterosacral Ligaments of Patients With and Without Pelvic Organ Prolapse. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2015, 21, 53-58. | 1.1 | 12 |
| 51 | Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor. <i>Gynecologic Oncology</i> , 2022, 166, 117-125. | 1.4 | 12 |
| 52 | Financial toxicity in patients with gynecologic malignancies: a cross sectional study. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e87. | 2.2 | 10 |
| 53 | DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. <i>Gynecologic Oncology</i> , 2021, 163, 334-341. | 1.4 | 10 |
| 54 | Subcellular localization and function of insulin-like growth factor 2 (IGF2) in uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2014, 133, 111. | 1.4 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Stratifying Ovarian Cancer Risk Using Personal Health Data. <i>Frontiers in Big Data</i> , 2019, 2, 24. | 2.9 | 8 |
| 56 | Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100667. | 0.6 | 8 |
| 57 | Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 500-504. | 2.5 | 6 |
| 58 | Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 719-726. | 2.5 | 6 |
| 59 | Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor. <i>Gynecologic Oncology Reports</i> , 2016, 15, 20-21. | 0.6 | 5 |
| 60 | Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. <i>Cancer Medicine</i> , 2018, 7, 616-625. | 2.8 | 5 |
| 61 | Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. <i>British Journal of Cancer</i> , 2022, 126, 1695-1703. | 6.4 | 5 |
| 62 | Genetic landscape of clear cell endometrial cancer and the era of precision medicine. <i>Cancer</i> , 2017, 123, 3216-3218. | 4.1 | 4 |
| 63 | Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A. <i>Cancer Research</i> , 2019, 79, 4009-4010. | 0.9 | 4 |
| 64 | Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2021, 162, S58. | 1.4 | 4 |
| 65 | Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. <i>Gynecologic Oncology</i> , 2021, 163, 557-562. | 1.4 | 4 |
| 66 | Neutrophilia and mortality in women with uterine carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1258-1263. | 2.5 | 3 |
| 67 | Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. <i>Gynecologic Oncology</i> , 2020, 158, 769-775. | 1.4 | 2 |
| 68 | Abstract 1080: Effect of IGF2 overexpression on the tumorigenicity of human ovarian carcinoma cells. , 2012, , . | | 2 |
| 69 | Antiproliferative activity of a phenolic extract from a native Chilean Amaranthaceae plant in drug-resistant ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2011, 120, S43. | 1.4 | 1 |
| 70 | ER-alpha, PR, EGFR and GPER expression differentially correlate with survival in endometrial carcinoma. <i>Gynecologic Oncology</i> , 2013, 130, e86. | 1.4 | 1 |
| 71 | Stage III uterine serous carcinoma: modern trends in multimodality treatment. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e53. | 2.2 | 1 |
| 72 | Consolidation therapy for ovarian cancer. <i>Women's Oncology Review</i> , 2005, 5, 3-8. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Tumor expression of the type I insulin-like growth factor receptor is an independent prognostic factor in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 120, S58. | 1.4 | 0 |
| 74 | Modulation of drug resistance in ovarian carcinoma cells by insulin-like growth factor-2 RNA interference. <i>Gynecologic Oncology</i> , 2012, 125, S135. | 1.4 | 0 |
| 75 | Predictors and incidence of radical vulvectomy complications in the modern era: A National Surgical Quality Improvement Program study. <i>Gynecologic Oncology</i> , 2013, 130, e38. | 1.4 | 0 |
| 76 | Evaluation of insulin-like growth factor 2 as a biomarker in uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2015, 137, 60-61. | 1.4 | 0 |
| 77 | Evaluation of a novel combination treatment strategy using patient-derived xenografts of uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2015, 137, 201-202. | 1.4 | 0 |
| 78 | High-risk Endometrial Cancer: The Present and Future of Adjuvant Therapy. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 23. | 0.2 | 0 |
| 79 | Charlson Comorbidity Index as a predictor of postoperative complication in octogenarians and nonagenarians with stage I endometrioid endometrial cancer: a single-institution retrospective review. <i>Gynecologic Oncology</i> , 2021, 162, S108. | 1.4 | 0 |
| 80 | In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, S186-S187. | 1.4 | 0 |
| 81 | Financial toxicity in patients with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2021, 162, S162. | 1.4 | 0 |
| 82 | Abstract 1809: Reversal of Taxol resistance in ovarian cancer cell lines by IGF pathway inhibition. , 2010, , . | | 0 |
| 83 | Abstract A33: in ovarian cancer cell lines resistant to microtubule-stabilizing agents, expression of IGF2 and ABCB1 is increased and IGF1R inhibition restores drug sensitivity. , 2010, , . | | 0 |
| 84 | Abstract A48: Effect of constitutive IGF2 overexpression on tumorigenicity of human ovarian carcinoma cells. , 2011, , . | | 0 |
| 85 | Abstract 948: In vivo evaluation of IGF2 RNA interference in a mouse xenograft model of paclitaxel-resistant human ovarian cancer. , 2013, , . | | 0 |
| 86 | RACGAP1 overexpression in uterine carcinosarcomas. <i>Journal of Clinical Oncology</i> , 2013, 31, e22009-e22009. | 1.6 | 0 |
| 87 | Abstract 5257: Immunohistochemical analysis and comprehensive hormone receptor profiling of uterine adenosarcomas at a single institution. , 2015, , . | | 0 |
| 88 | Abstract 5131: Establishment of uterine carcinosarcoma primary cell lines for chemosensitivity testing and evaluation of targeted therapy. , 2015, , . | | 0 |
| 89 | Evaluation of circulating neutrophils as a biomarker for outcomes in uterine carcinosarcoma. <i>Journal of Clinical Oncology</i> , 2016, 34, e17121-e17121. | 1.6 | 0 |
| 90 | Evaluating a novel oncologist-led <i>BRCA1/2</i> mutation (<i>BRCA</i> m) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study. <i>Journal of Clinical Oncology</i> , 2016, 34, e17048-e17048. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Assessment of BRCA testing uptake in ovarian cancer patients during the implementation of an oncologist-led genetic counseling model at an urban and suburban teaching hospital.. Journal of Clinical Oncology, 2017, 35, 1589-1589. | 1.6 | 0 |
| 92 | ENGAGE: Evaluation of a streamlined oncologist-led BRCA mutation (BRCAm) testing and counselling model for patients with ovarian cancer.. Journal of Clinical Oncology, 2017, 35, 5559-5559. | 1.6 | 0 |
| 93 | ARID1A interacts with nonmuscle myosin IIA to regulate cancer cell motility.. Journal of Clinical Oncology, 2019, 37, e17036-e17036. | 1.6 | 0 |
| 94 | Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.. Journal of Clinical Oncology, 2019, 37, 5509-5509. | 1.6 | 0 |
| 95 | Abstract 4851: Combination of letrozole plus abemaciclib is synergistic and suppresses tumor growth in ovarian and endometrial cancer models. , 2020, , . | | 0 |
| 96 | Consolidation therapy for ovarian cancer. Women's Oncology Review, 2005, 5, 3-8. | 0.0 | 0 |